论文部分内容阅读
目的:评价低分子量肝素(LMWH)治疗急性早幼粒细胞白血病(APL)合并弥漫性血管内凝血(DIC)的临床疗效。方法:回顾性分析2002年1月至2006年12月APL合并DIC住院患者18例,在治疗原发病、补充凝血因子及抗血小板治疗的同时加用低分子量肝素的疗效。结果:18例APL合并DIC患者中有12例治愈,显效5例,1例死亡,有效率94%。结论:低分子量肝素用于治疗APL合并DIC是经济、安全及有效的;而积极治疗原发病、补充凝血因子、抗血小板聚集治疗是治疗成败的关键。
Objective: To evaluate the clinical efficacy of low molecular weight heparin (LMWH) in the treatment of acute promyelocytic leukemia (APL) with diffuse intravascular coagulation (DIC). Methods: A retrospective analysis of 18 cases of APL and DIC inpatients from January 2002 to December 2006 was performed, and the effect of adding low-molecular-weight heparin was also observed in the treatment of primary disease, blood coagulation factor and antiplatelet therapy. Results: Of the 18 patients with APL combined with DIC, 12 were cured, 5 were markedly effective, 1 died, and the effective rate was 94%. Conclusion: Low molecular weight heparin is an economic, safe and effective treatment for APL combined with DIC; active treatment of primary disease, supplementation of coagulation factors, and anti-platelet aggregation therapy are the key to successful treatment.